Datapoint: AstraZeneca, Merck Pull Lynparza in Ovarian Cancer

AstraZeneca and Merck have moved to pull Lynparza’s approval as a fourth-line treatment for BRCA-mutated advanced ovarian cancer. Confirmatory phase 3 trial data showed an increased risk of death among Lynparza patients that had already received at least three other rounds of chemotherapy. The move follows GSK’s Sept. 14 decision to withdraw its own PARP inhibitor, Zejula, in previously treated ovarian cancer with homologous recombination deficiency. For the treatment of ovarian cancer, Lynparza currently holds covered or better status for 99% of all insured lives. 15% of lives have unrestricted preferred access to Lynparza, growing to 50% with restrictions applied.

SOURCE: MMIT Analytics, as of 9/28/22

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
November 23

Datapoint: Apellis Gets Updated Review Date for Eye Blockbuster Hopeful

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
November 22

Datapoint: Regence Sees 95% Biosimilar Adoption

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
November 17

Datapoint: Sanford, Fairview Health Announce Merger

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today